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Abstract 30 
Angiotensin II (Ang II) is the key hormone mediator of the renin angiotensin system which 31 
regulates blood pressure and fluid and electrolyte balance in the body. Here we report that in 32 
colonic epithelium the Ang II type 1 receptor (AT1R) is highly and exclusively expressed in 33 
enteroendocrine L-cells which produce the gut hormones glucagon-like peptide-1 (GLP-1) 34 
and peptide YY (PYY). Ang II stimulated GLP-1 and PYY release from primary cultures of 35 
mouse and human colon, which was antagonised by the specific AT1R receptor blocker 36 
candesartan. Ang II raised intracellular calcium levels in L-cells in primary cultures, recorded 37 
by live-cell imaging of L-cells specifically expressing the fluorescent calcium sensor 38 
GCaMP3. In Ussing chamber recordings, Ang II reduced short circuit currents in mouse distal 39 
colon preparations, which was antagonised by candesartan or a specific NPY1R receptor 40 
inhibitor but insensitive to amiloride. We conclude that Ang II stimulates PYY secretion, in 41 
turn inhibiting epithelial anion fluxes, thereby reducing net fluid secretion into the colonic 42 
lumen. Our findings highlight an important role of colonic L-cells in whole body fluid 43 
homeostasis by controlling water loss through the intestine.  44 
Introduction 45 
The prime functions of the gut are the digestion and absorption of ingested food. These are 46 
regulated by intestinal hormones, such as glucagon-like peptide-1 (GLP-1) and peptide YY 47 
(PYY), which are co-secreted from enteroendocrine L-cells found predominantly in the ileum 48 
and colon (1). Both hormones underlie the ileal break, slowing gastric emptying when 49 
nutrient delivery exceeds the absorptive capacity of the duodenum/jejunum, and control food 50 
intake and appetite (2). These effects beyond the confines of the intestine have raised interest 51 
in the exploitation of gut hormones for the treatment of diabetes and obesity. GLP-1 augments 52 
glucose induced insulin secretion (3), and has been exploited in the form of GLP-1 mimetics 53 
for the treatment of diabetes and obesity.  54 
An additional action of PYY is to inhibit intestinal water and anion secretion. This is achieved 55 
through a direct action on enterocyte Y1 receptors and an indirect effect on Y2 receptors 56 
located on enteric neurons(4). This paracrine effect of PYY is important for body fluid and 57 
electrolyte homeostasis. We showed previously that Arginine Vasopressin (AVP) stimulates 58 
GLP-1 and PYY release from mouse and human colonic L-cells and suggested that this forms 59 
part of a mechanism that reduces water loss through the intestine (5). Another important 60 
regulator of water and electrolyte balance and blood pressure is the renin angiotensin system 61 
(RAS) (reviewed in (6)), which exhibits both systemic and local regulation. Sympathetic 62 
stimulation, renal artery hypotension or reduced blood volume (e.g. dehydration or 63 
haemorrhage) initiate the release of renin from renal juxtaglomerular cells which converts 64 
circulating angiotensinogen to angiotensin I (Ang I). Ang I in turn is hydrolysed by 65 
angiotensin converting enzyme (ACE) to form the biologically active octapeptide 66 
Angiotensin II (Ang II). Ang II causes arterial vasoconstriction and renal retention of sodium 67 
and fluid, and stimulates the release of aldosterone and AVP from the adrenal cortex and 68 
posterior pituitary, respectively.  69 
Several studies have identified different components of the RAS, including angiotensinogen, 70 
renin, ACE, Ang II and angiotensin receptors in the mucosal and muscular layers of the 71 
gastro-intestinal tract (7-10). Angiotensin receptors, particularly AT1, have been implicated in 72 
gut motility (11,12) and electrolyte absorption (13-15). Here we report that AT1 is highly and 73 
selectively expressed in colonic L-cells, and is linked to the stimulation of PYY and GLP-1 74 




Solutions and compounds 79 
All compounds were purchased from Sigma Aldrich (Poole, U.K.) unless otherwise stated. 80 
BIBP 32267 trifluoroacetate was purchased from Bioquote (York, U.K.) and Angiotensin (1-81 
7) from Bio-Techne (Abingdon, U.K.). The composition of the standard bath solution used in 82 
secretion and imaging experiments was: 4.5 mmol/L KCl, 138 mmol/L NaCl, 4.2 mmol/L 83 
NaHCO3, 1.2 mmol/L NaH2PO4, 2.6 mmol/L CaCl2, 1.2 mmol/L MgCl2 and 10 mmol/L 84 
HEPES (adjusted to pH 7.4 with NaOH). For experiments where CoCl2 was used, carbonates 85 
and phosphates were omitted from the saline buffer and the osmolarity was compensated with 86 
additional NaCl (143 mmol/L total). The composition of Ringer’s solution used in Ussing 87 
chamber experiments was: 120 mmol/L NaCl, 3 mmol/L KCl, 0.5 mmol/L MgCl2, 1.25 88 
mmol/L CaCl2, 23 mmol/L NaHCO3 and 10 mmol/L glucose. 89 
 90 
Animals and ethical approval 91 
All animal procedures were approved by the University of Cambridge Animal Welfare and 92 
Ethical Review Body and conformed to the Animals (Scientific Procedures) Act 1986 93 
Amendment Regulations (SI 2012/3039). The work was performed under the UK Home 94 
Office Project License 70/7824. Male and female mice, aged 3-6 months on a C57BL6 95 
background were housed in individually-ventilated cages on a 12h dark/light cycle with ad 96 
libitum access to water and chow. Mice were euthanized by cervical dislocation and intestinal 97 
tissue used in the experiments. For in vivo experiments, only male mice, aged 11-12 weeks 98 
were used. Mice were fasted overnight for a maximum of 16 hours before receiving an intra-99 
peritoneal injection of either Ang II (100 µg/kg) or PBS (vehicle). Ten minutes after the 100 
injection, each animal was anaesthetised (isoflurane) and a terminal blood sample taken. 101 
Blood was collected in tubes containing EDTA and protease inhibitors (10 µmol/L amastatin 102 
hydrochloride, 100 µmol/L diprotinin A, 18 µmol/L aprotinin), centrifuged at 13,000 g for 90 103 
s, and plasma collected and used for active GLP-1 and total PYY analysis.  104 
 105 
Transgenic Mice 106 
GLU-Venus and GLU-Cre mice have been previously described (16) (17) and express the 107 
fluorescent protein Venus and Cre recombinase under the control of the proglucagon 108 
promoter, respectively. To monitor calcium fluctuations in L-cells, GLU-Cre mice were 109 
crossed with ROSA26-GCaMP3 reporter mice (18) (Jax stock 014538) to generate L-cell 110 
specific expression of the genetically encoded Ca
2+
 sensor.   111 
 112 
Primary murine colonic crypt cultures 113 
Colonic crypts were isolated and cultured as previously described (16). Briefly, mice 3-6 114 
months old were sacrificed by cervical dislocation and the colon was excised. Luminal 115 
contents were flushed thoroughly with PBS and the outer muscle layer removed. Tissue was 116 
minced and digested with Collagenase Type XI (0.4 mg/ml) and the cell suspension plated 117 
onto Matrigel (BD Bioscience, Oxford, UK) pre-coated 24-well plates for GLP-1 secretion 118 
experiments or on 35mm glass bottomed dishes (Mattek Corporation, MA, USA) for live cell 119 
calcium imaging.  120 
 121 
Preparation of crypt cultures from human colons  122 
The study was approved by the Research Ethics Committee under license number 123 
09/H0308/24. Fresh surgical specimens of human colon were obtained from Tissue Bank at 124 
Addenbrooke’s Hospital, Cambridge, UK, stored at 4oC and processed within a few hours of 125 
surgery. The crypt isolation procedure was similar to that used for mouse tissue with the 126 
exception that a higher concentration of collagenase XI (0.5 mg/ml) was used for digestion 127 
(1).  128 
 129 
GLP-1 and PYY secretion assays 130 
18-24 hours after plating, cells were washed and incubated with test agents dissolved in 131 
standard bath solution supplemented with 0.1% BSA for 2 hours at 37
o
C. At the end of the 132 
incubation, supernatants were collected and centrifuged at 2000 rcf for 5 minutes and snap 133 
frozen on dry ice. Cells were lysed with lysis buffer containing 50 mmol/l Tris-HCl, 150 134 
mmol/L NaCl, 1% IGEPAL-CA 630, 0.5% deoxycholic acid and complete EDTA-free 135 
protease inhibitor cocktail (Roche, Burgess Hill, UK) to extract intracellular peptides, 136 
centrifuged at 10,000 rcf for 10 minutes and snap frozen. GLP-1 and PYY were measured 137 
using total GLP-1 and total PYY assays (MesoScale Discovery (MSD), Gaithersburg, MD, 138 
USA) and supernatant concentrations were expressed as a percent of the total 139 
(secreted+lysate) GLP-1 or PYY content of each well.    140 
 141 
Calcium imaging 142 
L-cell cytosolic calcium concentrations were monitored as intensity changes in GCaMP3 143 
fluorescence excited at 488nm using a xenon arc lamp and a monochromator (Cairn Research, 144 
UK) in colonic crypt cultures prepared from GLU-Cre/ROSA26-GCaMP3 mice. Solutions 145 
were perfused continuously at a rate of approximately 1 ml/min. Imaging was performed 146 
using an Olympus IX71 microscope with a 40x oil immersion objective and an OrcaER 147 
camera (Hamamatsu, Japan). Images were acquired at 1 Hz and analysed, after background 148 
subtraction, using MetaFluor software (Molecular Devices, USA). Fluorescence in the 149 
presence of the test agent was normalised to the respective mean background fluorescence of 150 
each cell, measured before the addition and after the washout of the test compound. For 151 
presentation data were smoothened with a sliding average over 20s. 152 
Microarray analysis and RNA sequencing 153 
Microarray analysis of total RNA from FACS purified L-cells using Affymetrix mouse 430 154 
2.0 expression arrays (Affymetrix UK Ltd, high Wycombe, UK) has been described 155 
 
previously (19). Expression levels of each probe were determined by robust multichip average 156 
(RMA) analysis. For sequencing, total RNA from 2,000 to 10,000 FACS purified L-cells 157 
from the upper small intestine (top 10 cm), lower small intestine (bottom 10 cm) or 158 
colon/rectum  from GLU-Venus mice was extracted using an RNeasy Micro Plus kit 159 
(QIAGEN) according to the manufacturer’s instructions. RNA was amplified using Ovation 160 
RNA-seq System V2 (NuGEN), using 1 ng of RNA for each sample (3 replicates each were 161 
used for L-cells and non-fluorescent control cells for each segment of the gastrointestinal 162 
tract, totalling 18 samples). To prepare the RNAseq library, the amplified cDNA (1µg per 163 
sample) was fragmented to 200 bp using a Bioruptor Sonicator (Diagenode), and barcode-164 
ligation and end repair were achieved using the Ovation Rapid DR Multiplex System 1-96 165 
(NuGEN). Barcoded libraries were combined and sent for SE50 sequencing using an Illumina 166 
HiSeq 2500 system at the Genomics Core Facility, Cancer Research UK Cambridge Institute. 167 
Sequence reads were demultiplexed using the Casava pipeline (Illumina) and then aligned to 168 
the mouse genome (GRCm38) using Tophat version 2.1.0 (http:// 169 
ccb.jhu.edu/software/tophat/index.shtml). Differential gene expression was determined using 170 
Cufflinks version 2.2.1 (http://cole-trapnell-lab.github.io/cufflinks/). 171 
 172 
Quantitative RT-PCR  173 
Populations of Venus-positive cells (L-cells) or Venus-negative cells (non-L cells) of purity 174 
>90% were separated from the tissues of GLU-Venus mice using a BD Influx cell sorter 175 
running BD FACS Software as previously described (16).  Laser alignment was performed 176 
using eight-peak rainbow beads (Spherotech), and drop delay was determined using BD 177 
Accudrop beads. RNA was extracted from FACS-sorted cells by a microscale RNA isolation 178 
kit (Ambion, Austin, TX, USA) and reverse transcribed to cDNA according to standard 179 
protocols. First-strand cDNA template was mixed with specific TaqMan primers (Applied 180 
Biosystems, Foster City, CA, USA), water and PCR Master Mix (Applied Biosystems), and 181 
quantitative RT-PCR was conducted using a 7900HT Fast Real-Time PCR system (Applied 182 
Biosystems). β-Actin was used as the normalisation control. The primer/probe pairs used in 183 
this study were from Applied Biosystems, Agtr1: Mm01957722_s1 and 184 
Mas1:Mm00434823_s1. All experiments were performed on at least three cDNAs isolated 185 
from one mouse each. 186 
 187 
Immunohistochemistry 188 
Tissues were fixed in 4% paraformaldehyde, dehydrated in 15% and 30% sucrose, and frozen 189 
in optimal cutting temperature embedding media (CellPath, Newtown, U.K.). Cryostat-cut 190 
sections (6–10 µm) were mounted directly onto polylysine-covered glass slides (VWR, 191 
Leuven, Belgium). Slides were incubated for 1 h in blocking solution containing PBS/0.05% 192 
Triton X-100/10% donkey serum and overnight with primary antibodies (goat anti- GLP-1 193 
(sc-7782) and rabbit anti-AT1R (sc-579, Santa Cruz Biotechnology Inc, CA, USA) in 194 
blocking solution. Sections were rinsed with blocking solution before being incubated for 1 195 
hour at room temperature with Alexa Fluor 488 (1:300) and Alexa Fluor 555 (1:300) 196 
secondary antibodies (Invitrogen) and Hoechst (1:1300) for nuclear staining. Control sections 197 
were stained with secondary antibodies alone. Sections were mounted with Prolong Gold 198 
(Life Technologies) before being imaged by confocal microscopy (Leica TCS SP8, Milton 199 
Keynes, U.K.). 200 
Ussing Chamber recordings 201 
The most distal part of the colon (~1.25 cm) was cut open longitudinally and rinsed in 202 
Ringer’s solution. Serosa and most of the outer muscular layer were removed by fine forceps. 203 
The tissue was mounted in an Ussing chamber (EM-LVSYS-4 system with P2400 chambers 204 
and P2404 sliders, all from Physiologic Instruments, San Diego, CA, USA). Only one 205 
preparation was used from each animal. The active epithelial surface was 0.25 cm
2
. Both parts 206 
of the Ussing chambers were filled with 3 ml of Ringer’s solution, maintained at 37oC and 207 
continuously bubbled with 5% vol/vol CO2/ 95% vol/vol O2. The transepithelial potential 208 
difference was clamped to 0 mV using a DVC 1000 amplifier (WPI, Sarasota, FL, USA) and 209 
the resulting short circuit current was recorded through Ag-AgCl electrodes and 3 mol/L KCl 210 
agarose bridges. The recordings were collected and stored using Digidata 1440A acquisition 211 
system and AxoScope 10.4 software (both from Molecular Devices, Sunnyvale, CA, USA). 212 
The transepithelial resistance and short circuit current (Isc) were allowed to stabilise for at 213 
least 30 minutes before the application of drugs. During this period, transepithelial resistance 214 
was assessed by measuring current changes in response to 2 mV pulses lasting 2.5 seconds, 215 
applied every 100 s. After stabilisation of the electrical parameters, the following drugs were 216 
applied: 5 µmol/L amiloride, 1 µmol/L candesartan, 1 µmol/L BIBP 3226, and 1 µmol/L Ang 217 
II. Forskolin (10 µmol/L) was applied bilaterally at the end of each experiment to confirm the 218 
responsiveness/viability of the tissue. As Ang II triggered a sustained depression in Isc in all 219 
tissue preparations tested, but a short-lived increase (1-3 min duration) in only ~half  the 220 
preparations, the difference between the mean Isc 2-5 min immediately preceding, and the 221 
mean Isc during 30 minutes following Ang II application was used to combine data from 222 
different preparations.  223 
Statistics 224 
Results are expressed as mean ± SD unless otherwise indicated. Statistical analysis was 225 
performed using GraphPad Prism 5.01 (San Diego, CA, USA). For GLP-1 and PYY secretion 226 
data, one-way ANOVA with post hoc Dunnett’s or Bonferroni tests were performed on log-227 
transformed secretion data, as these data were heteroscedastic. For Ussing chamber 228 
recordings, one-way ANOVA with post hoc Dunnett’s test was performed on non-229 
transformed Isc data normalised for a surface area of 1 cm
2
. For qRT-PCR, one-way ANOVA 230 
with post hoc Bonferroni analysis was done on non-transformed ΔCt data. Statistical 231 
significance for Ca
2+
 imaging data was assessed by Student’s t-test.  232 
Results 233 
AT1 receptor expression in mouse and human colonic L-cells  234 
Ang II interacts with two seven-transmembrane G-protein coupled receptors, AT1 and AT2. 235 
Whereas rodents possess two AT1 receptor isoforms, AT1A and AT1B (encoded by Agtr1a and 236 
Agtr1b, respectively) (20) humans have only one type 1 receptor gene. Microarray analysis 237 
was performed to compare the expression of Agtr1a, Agtr1b and Agtr2 in primary murine 238 
glucose-dependent insulinotropic polypeptide (GIP) secreting K-cells as well as L-cells from 239 
the duodenum/jejunum (top 10 cm of the small intestine (LD) or the colon. As shown in 240 
Figure 1A, Agtr1a expression was ~100-fold higher in colonic (LC) than upper SI L-cells 241 
(LDJ), and 14-fold enriched in colonic L-cells (LC) over non-L-cells (CC). Agtr1b and Agtr2 242 
were poorly expressed in all cell populations examined (Figure 1A). RNA-sequencing 243 
confirmed the high selective expression of Agtr1a in colonic L-cells (LC, Figure 1B). 244 
Microarray and RNA-seq results were also validated by quantitative PCR, performed on 245 
cDNA prepared from independently FACS-sorted L- and non L-cells from the upper SI 246 
(duodenum/jejunum, LDJ), the lower SI (jejunum/ileum, LJI) and colon (LC) as well as K-247 
cells and non K-cells. By q-PCR, Agtr1a was highly enriched in colonic L-cells (LC) over 248 
colonic control cells (CC), and was found at much lower levels in small intestinal epithelial 249 
control (CDJ, CJI) and L-cells (LDJ, LJI) and K- and non-K-cells (CK) (Figure 1C). 250 
In human colon tissue sections, AT1 immuno-positive cells were found scattered through the 251 
epithelium and co-stained with antibodies against GLP-1(Fig 1D). No visible staining for AT1 252 
was detected in GLP-1 negative cells of the epithelial layer. Some cells in the lamina propria 253 
showed AT1 reactivity, but their identity was not further investigated (data not shown).  254 
Ang II stimulated GLP-1 and PYY secretion from mouse and human colon cultures  255 
The functional relevance of the high Agtr1a expression in mouse colonic L-cells was 256 
investigated by performing hormone secretion experiments from primary murine colonic 257 






 mol/L) or with a 258 
positive control containing a combination of forskolin (10 µmol/L), IBMX (10 µmol/L) and 259 
glucose (10 mmol/L). Ang II stimulated GLP-1 secretion at all concentrations tested. The 260 
highest concentration, 10
-6
 mol/L, increased GLP-1 secretion from 3% to 9.5% of the total 261 
GLP-1 content (Figure 2A). Secretion of PYY, which is co-released from colonic L-cells, was 262 
examined with a single concentration of Ang II (10
-8
 mol/L), and increased from 8.5% to 24% 263 
of the total PYY content (Figure 2B). Consistent with the localisation of AT1 in human 264 
colonic L-cells, Ang II (10
-6
 mol/L) also enhanced GLP-1 and PYY secretion by ~1.4-fold 265 
each (Fig 2C and 2D) in human colonic crypt cultures. In mice, acute intra peritoneal 266 
injection of Ang II (100 µg/kg) did not, however, significantly increase plasma GLP-1 or 267 
PYY concentrations (Fig 2E and 2F). 268 
GLP-1 and PYY secretion is mediated by AT1 receptor 269 
To investigate if other receptors for Ang II or its metabolites play a role in Ang II stimulated 270 
hormone secretion from the colon, we performed secretion experiments in the presence of 271 
Candesartan cilexetil, a prodrug used to treat hypertension, which is converted to the selective 272 
AT1 inhibitor Candesartan by the intestinal wall esterases (21). Candesartan (Can, 10
-7
 mol/L) 273 
had no effect on basal GLP-1 secretion, but abolished Ang II triggered GLP-1 release from 274 
mouse colonic cultures (Figure 3A). Ang II triggered PYY secretion was also blocked by co-275 
treatment with Candesartan (Figure 3B), thereby establishing the role of AT1 in mediating 276 
Ang II stimulated GLP-1 and PYY secretion.  277 
Ang II induced intracellular calcium responses in colonic L-cells 278 
Previous studies have revealed that AT1 receptors activation recruits phospholipase C and 279 
stimulates the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) to diacylglycerol 280 
(DAG) and inositol-1,4,5-trisphosphate (IP3), promoting calcium release from internal stores 281 
(22,23). Depending on the cell or tissue type, it was also reported that Ang II inhibits 282 
adenylate cyclase and lowers intracellular cAMP levels (24,25). To elucidate the mechanistic 283 
pathway involved in Ang II-triggered GLP-1 and PYY release, we monitored the changes in 284 
intracellular calcium in primary colonic L-cells identified in cultures from GLU-285 
Cre/ROSA26-GCaMP3 mice during Ang II application. As shown in Figure 4A, Ang II 286 
triggered a rapid increase in L-cell GCaMP3 fluorescence, indicative of an increase in the 287 
intracellular calcium concentration. Responses peaked shortly after Ang II addition, were 288 
rapidly reversible, and were reproducible on second application of Ang II (Figure 4A &B).  289 
Intracellular calcium can be increased either by opening of plasma membrane calcium 290 
channels or by release from intracellular calcium stores. To establish whether the Ang II 291 
dependent cytoplasmic calcium rise was due to calcium release from intracellular 292 
endoplasmic reticulum stores or the opening of plasma membrane voltage-gated calcium 293 
channels, calcium imaging experiments were performed in the presence of cobalt chloride 294 
(CoCl2), a general voltage gated calcium channel blocker that impairs L-cell calcium 295 
responses to depolarising stimuli such as KCl (26).  Cytoplasmic calcium responses to Ang II 296 
were still observed in the presence of CoCl2 (5 mmol/l) (Fig 4C and D), suggesting they do 297 
not depend on voltage gated calcium channels. This is consistent with the reported Gq 298 
coupled nature of AT1 (27).Further corroborating the results obtained with calcium imaging 299 
experiments, the L-type voltage gated calcium channel blocker nifedipine (10µmol/L) did not 300 
significantly inhibit Ang II stimulated GLP-1 secretion (Fig4E), but GLP-1 responses to Ang 301 
II were blocked by 2-aminoethoxydiphenylborate (2- APB, 100µmol/L), an inhibitor of IP3 302 
receptors (Fig 4E). 303 
Non classical RAS and L-cells 304 
Whereas the classical RAS (ACE-Ang II-AT1) promotes actions to maintain blood pressure, a 305 
‘non-classical’ RAS, consisting of ACE2-Ang (1-7)-Mas1 receptor has opposing effects (28). 306 
Ang (1-7) is generated by the cleavage of an amino acid from the carboxy-terminus of Ang II 307 
by an ACE homologue ACE2 and mediates vasodilatory/diuretic actions through the 308 
AT7/Mas1 receptor (29). Microarray (Fig 5A) and RNA-seq analysis (data not shown) for 309 
Mas1 receptor expression were performed on K- and L-cells from mouse upper SI (LDJ) and 310 
colon (LC) and their respective control cells (CK, CDJ, CC). Mas1 expression was very low 311 
or undetectable in all cell populations examined. This was confirmed by qPCR (Fig 5B). 312 
Consistent with these findings, application of Ang (1-7) to primary murine colonic crypt 313 
cultures had no significant effect on GLP-1 release (Fig 5C).  314 
Antisecretory effect of Ang II in mouse colon 315 
Given the well-known inhibitory effect of PYY on intestinal anion and water secretion 316 
(4,5,30-32), we employed Ussing chambers to study the functional relevance of Ang II in 317 
mouse colon. In all tissue preparations tested, basolateral addition of Ang II (10
-6
 mol/L) 318 
caused a sustained depression in Isc (of mean 15.1 µA/cm
2
) lasting for at least 35 minutes 319 
(Fig 6A). In 3/5 preparations we also observed a transient increase in Isc, with a peak increase 320 
of 40.6 ± 10.1 µA/cm
2 
(Fig 6A), but this was absent in the other 2 preparations (not shown). 321 
Pre-treatment with apically-added amiloride (5 µmol/L) alone decreased Isc, which came to a 322 
new plateau 9.6 ± 9.1 µA/cm
2
 lower than the Isc before amiloride addition. Subsequent 323 
application of Ang II 10-12 minutes after amiloride pre-treatment caused further Isc 324 
depression, which was not different from the response caused by Ang II without any pre-325 
treatment (Fig 6D). These results suggest that the Ang II-related Isc decrease was due to 326 
inhibition of electrogenic anion secretion and did not involve ENaC-dependent sodium 327 
absorption. Pre-treatment with basolaterally-added BIBP3226 (BIBP, a specific NPY1R 328 
antagonist) caused an increase of Isc, with the new plateau being 1.8 ± 2.7 µA/cm
2
 higher 329 
than before BIBP addition. The inhibitory Isc response to Ang II applied 10-12 minutes after 330 
BIBP was significantly impaired, confirming a role of the PYY receptor NPY1R in Ang II 331 
mediated changes of colonic transepithelial ion movement (Fig 6B and 6D). Candesartan (10
-6
 332 
mol/L bilaterally) reduced the basal Isc by1.9 ± 2.8 µA/cm
2
, and abolished any subsequent 333 
responses to Ang II application, confirming the role of AT1 in Ang II stimulated Isc changes 334 
(Fig 6C and 6D).  335 
The above-mentioned initial short-lived (1-3mins) Isc increase after Ang II addition was 336 
observed in 2/4 preparations pre-treated with amiloride, 2/4 preparations pre-treated with 337 
BIBP and 0/4 preparations pre-treated with Candesartan. When considering all preparations 338 
together, there was no significant difference in the early peak magnitude between the groups 339 
(data not shown). 340 
Discussion 341 
Digestion and absorption of nutrients from the intestine depends on sufficient availability of 342 
water in the lumen. Indeed, in addition to the average ingested fluid volume of ~2.5 litres per 343 
day in humans, it has been estimated that 5-10 litres of water are secreted into the gut lumen 344 
and re-absorbed to aid intestinal processes (33), necessitating a close link between the gut and 345 
systems regulating body fluid and electrolyte homeostasis. Here we identified AT1 in colonic 346 
L-cells and demonstrated that its activation by Ang II triggered GLP-1 and PYY secretion and 347 
downstream PYY-dependent inhibition of anion secretion. This offers a potential explanation 348 
for previous reports that colonic fluid secretion is regulated by the renin angiotensin system 349 
(15).   350 
The effect of Ang II on intestinal water and ion absorption has been studied extensively in the 351 
rat. At low physiological concentrations Ang II stimulates water absorption in the jejunum 352 
and colon, although higher doses were also reported to inhibit absorption (15). In the jejunum 353 
the pro-absorptive effect of Ang II was linked to the activation of noradrenergic nerve 354 
endings, based on the sensitivity of the response to -adrenergic antagonists (34). Early 355 
investigations concluded that the proabsorptive effects of Ang II are predominantly mediated 356 
by electroneutral mechanisms (13), but experiments on rat descending colon mounted in 357 
Ussing chambers revealed a reduction of ISC over a wide Ang II concentration range (10
-9
 – 358 
10
-5
 mol/L) (14). This was sensitive to the chloride channel blocker, diphenylamine-2-359 
carboxylate (DPC) but not to amiloride, suggesting that the action of Ang II on Isc is 360 
mediated through inhibition of anion secretion rather than stimulation of electrogenic sodium 361 
absorption (14). Our observed decrease in Isc in the colon is in agreement with these results 362 
and is clearly mediated via AT1 as it was sensitive to candesartan. In about half the 363 
preparations, we also observed a transient increase in Isc – this might also be downstream of 364 
AT1 as it was never observed in the presence of candesartan, but in contrast to the sustained 365 
Isc reduction, it was not affected by the Y1-receptor antagonist BIBP3226. Our finding that 366 
the sustained reduction in Isc by Ang II was sensitive to BIBP3226 and insensitive to 367 
amiloride suggests that this effect lies downstream of PYY secretion. PYY, in addition to 368 
slowing gastric emptying and reducing hunger, is well recognised as an inhibitor of anion and 369 
electrolyte secretion (35), exerting its inhibitory action mainly via Y1 receptors on 370 
enterocytes and to some extent by Y2 receptors on enteric neurons (31). Activation of the 371 
Gi/Go coupled Y1 receptor lowers intracellular enterocyte cAMP levels, subsequently 372 
inhibiting CFTR channels, and thereby reduces anion secretion into the gut lumen (4). 373 
Previous studies have shown that AT1 is the predominant Ang II receptor in the muscularis of 374 
rat ileum and colon (7), submucosal plexus in guinea pig distal colon (36), vessel walls, 375 
myofibroblasts, and macrophages in the lamina propria, crypt bases and surface epithelium in 376 
human colon (9), as well as a subset of human jejunal cells resembling enteroendocrine cells 377 
(37). Our data contrast with the previously-reported detection of AT1 in jejunal enterocytes 378 
(37), as we found only very low mRNA expression in the non-L-cell population of the mouse 379 
small intestine, which would be dominated by enterocytes. While this might reflect species 380 
differences, we also observed clear AT1 staining in human colonic L-cells but not enterocytes. 381 
The fact that we were able to block the sustained drop of short circuit current observed in 382 
Ussing chamber mounted colonic tissue in response to Ang II with the Y1R-blocker 383 
BIBP3226 is consistent with the observed restriction of AT1 to L-cells in the murine colon 384 
and an important role of L-cells in the secretory responses of the colon to Ang II. 385 
Although Ang II could in principle also exert some of its effects through other receptors, we 386 
were unable to demonstrate a role of other angiotensin receptors in L-cells. mRNAs encoding 387 
both AT2, which has a similar affinity for Ang II as AT1, and the MAS1 receptor were only 388 
expressed at very low levels, barely detectable by RT-PCR. Ang (1-7), the ligand for MAS1, 389 
had no effect in GLP-1 secretion. The effects on gut hormone secretion of other angiotensin 390 
derived peptides such as Ang III and Ang IV have not been studied and a possible function 391 
cannot be ruled out. However, candesartan, a specific antagonist for AT1, completely 392 
abolished Ang II-triggered GLP-1 and PYY secretion, emphasising the predominant role of 393 
this receptor for Ang II stimulated gut hormone release.  In keeping with the known Gq-394 
coupling of AT1 in heterologous expression systems, we observed Ang II triggered Ca
2+
-395 
responses that were maintained in the presence of extracellular Co
2+
 - a treatment that 396 
eliminates Ca
2+
-rises downstream of voltage gated Ca
2+
-channels in L-cells (38). Consistent 397 
with these results, nifedipine, which blocks L-type voltage gated Ca
2+
-channels and inhibits 398 
GLP-1 secretion from L-cells (39), had no significant effect on Ang II stimulated secretion. 399 
Sensitivity of the secretory-response in L-cells to 2-APB, an inhibitor of IP3-receptors, is 400 
consistent with the recruitment of ER-stores, although we cannot exclude additional 401 
contributions from plasma membrane channels such as TRP-channels, a number of which are 402 
expressed in L-cells (38) sensitive to 2-APB.  403 
Physiological relevance 404 
Our results suggest that physiological activation of the renin angiotensin system will be 405 
accompanied by increased colonic GLP-1 and PYY secretion, and are in keeping with our 406 
previous report that colonic L-cells are also activated by AVP. Whereas PYY likely exerts 407 
local actions on fluid secretion, it is not known whether Ang II-dependent stimulation of 408 
colonic L-cells would be sufficient to elevate circulating GLP-1 and PYY levels and trigger 409 
anorexigenic and insulinotropic responses. Chronic infusion of Ang II at a rate of 1.5 410 
g/(kg*min) has been shown to reduce food intake in C57B6 mice in a candesartan sensitive 411 
manner (40). While no changes in intestinal hormone mRNA expression were observed, 412 
circulating hormone levels were not reported. However, we failed to detect significant 413 
changes in plasma GLP-1 or PYY in response to intraperitoneal Ang II injection (100 g/kg), 414 
a supraphysiological dose chosen ~3-20-fold in excess of doses previously reported to affect 415 
taste behaviour (41) and blood pressure (42) in mice. While this might support the view that 416 
the well documented anorexic effects of Ang II are downstream of direct action in the central 417 
nervous system (43), it is also well known that anorexic effects of enteroendocrine hormones 418 
are at least in part mediated via afferent neuronal fibers, which could be stimulated by local 419 
elevations of gut hormones insufficient to raise plasma levels (2). 420 
Despite the enrichment of AT1 receptors in colonic L-cells and the finding that AT1 receptor 421 
activation triggered GLP-1 and PYY release, these receptors would not seem a promising 422 
target for drug discovery in the field of L-cell secretagogues. Although it has been proposed 423 
that local AT1 agonism in the jejunum might beneficially reduce SGLT1-mediated glucose 424 
absorption (37,44), the potential benefits of targeting intestinal AT1 receptors do not weigh 425 
favourably against the evident clinical cardiovascular benefits of ACE inhibitors and 426 
angiotensin receptor blockers. Nevertheless, the finding that AVP and angiotensin receptors 427 
are highly enriched in colonic L-cells raises the concept of an important cross-talk between 428 
colonic enteroendocrine cells and fluid balance regulatory pathways, and raises interesting 429 
questions about the physiological control and functional roles of colonic hormones.  430 
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  574 
Figure Legends 575 
Figure 1: Angiotensin II type 1 receptor (AT1R) is highly and exclusively present in 576 
colonic L-cells. Gene expression of Agtr1a, Agtr1b and Agtr2 was examined by (A) 577 
microarray analysis from FACS-sorted mouse K-cells (K), upper small intestinal 578 
(duodenal/jejunal) L-cells (LDJ) and colonic L-cells (LC), together with corresponding non-579 
fluorescent control cells collected in parallel (CK, CDJ, CC, respectively) and by (B) RNA-580 
sequencing on FACS- sorted L-cells and controls from mouse duodenum/jejunum (LDJ, 581 
CDJ), jejunum/ileum (LJI, CJI) and colon (LC, CC). (C) Agtr1a expression was validated by 582 
q-RT PCR in mouse K-, L- and control cells. Data are presented as the geometric mean + 583 
upper SEM of the 2ΔCt data (n ≥ 3 each). Comparisons between L-cells and controls were 584 
assessed on non-transformed ΔCt data using one-way ANOVA and post hoc Bonferroni 585 
analysis. ***P < 0.001. (D) Representative photomicrograph demonstrating co-localisation of 586 
GLP-1 (green) and AT1R (red) in 4% PFA fixed human colon tissue section. Nuclei were 587 
visualised with Hoechst staining (blue). Scale bar is 10 µm.  588 
Figure 2: Angiotensin II stimulates GLP-1 and PYY secretion from mouse and human 589 
colon cultures. (A) GLP-1 secretion was measured from mouse mixed colon cultures 590 
incubated for 2 h in saline solution alone (Control; Con) or containing increasing 591 
concentrations of Ang II. (B) PYY secretion was measured from mixed cultures incubated 592 
with Ang II (10 nmol/L) or forskolin (10 μmol/L) plus IBMX (10 μmol/L) plus glucose (10 593 
mmol/L) (F/I/G). GLP-1 and PYY secretion is expressed as a percentage of total hormone 594 
content in each well. Similarly, GLP-1 (C) and PYY (D) secretion was measured from human 595 
colon cultures incubated with Ang II (10 nmol/L) or F/I/G.  Results are shown as the mean + 596 
SEM of (A) n = 12, (B) n = 13-14, (C) n= 11-14, (D) n=11-15 wells with 3 or 4 wells 597 
originating from a single mouse or human tissue sample. *P<0.05, **P<0.01, ***P < 0.001 598 
compared to controls using one-way ANOVA followed by post hoc Bonferroni analysis on 599 
log10 transformed data. Active GLP-1 (E) and total PYY (F) levels were measured in plasma 600 
of mice that received a single intra-peritoneal injection of either Ang II (100 g/kg) or PBS 601 
(vehicle). Mean ± SEM from 6-7 mice per group are depicted. 602 
Figure 3: Antagonism of AT1 receptor reduces GLP-1 and PYY secretion from mouse 603 
colon cultures. GLP-1 (A) and PYY (B) secretion was measured from colon cultures treated 604 
with Ang II (10 nmol/L) in the presence or absence of Candesartan cilexetil (Can. 1 μmol/L), 605 
a selective AT1 receptor antagonist. Where applicable, wells were pre-treated with Can. 30 606 
min before the administration of Ang II. GLP-1 and PYY secretion is expressed as a 607 
percentage of total content. Results are shown as the mean + SEM; n = 9–12 wells with 3 or 4 608 
wells originating from a single mouse. ***P < 0.001 compared to controls or as indicated 609 
using one-way ANOVA followed by post hoc Dunnett's test or Bonferroni analysis on log10 610 
transformed data. 611 
Figure 4: Ang II elevates intracellular calcium responses in colonic L-cells. (A) A 612 
representative trace showing calcium response to Ang II (10 nmol/L) in a L-cell from a mixed 613 
colon culture imaged by GCaMP3 fluorescence. (B) Mean normalised GCaMP3 fluorescence 614 
changes in L-cells exposed to two successive applications of Ang II, recorded as in (A). n = 6 615 
cells and results are the mean + SEM. ***P < 0.001 compared to baseline by one-sample 616 
Student's t test. (C) A representative trace showing calcium response to Ang II (10 nmol/L) in 617 
the presence of cobalt chloride (CoCl2; 5 mmol/L) to block voltage-gated calcium channels 618 
and (D) mean GCaMP3 fluorescence changes in L-cells in response to Ang II (10 nmol/L) in 619 
the presence of CoCl2 (n = 12 cells). Results are shown as the mean + SEM. ***P < 0.001 620 
compared to baseline by a one-sample Student's t test. (E) GLP-1 secretion from mouse mixed 621 
colon cultures stimulated with Ang II (10 nmol/L) in the presence or absence of nifedipine 622 
(Nif, 10 µmol/L) or 2-APB (100 µmol/L). Where applicable, wells were pre-treated with 623 
nifedipine or 2-APB 30 min before the administration of Ang II. GLP-1 secretion is expressed 624 
as a percentage of total content. Results are shown as the mean + SEM; n = 10–12 wells with 625 
3 or 4 wells originating from a single mouse. ***P < 0.001 compared to controls or ##P <0.01 626 
compared to Ang II alone as indicated, using one-way ANOVA followed by post hoc 627 
Dunnett's test or Bonferroni analysis on log10 transformed data. 628 
Figure 5: Ang (1-7) and the Mas-1 receptor are not involved in GLP-1 secretion. Mas1 629 
receptor expression was analysed by (A) Microarray analysis on FACS-sorted K-, and L- 630 
cells from duodenum/jejunum (LDJ) and colon (LC) and respective control cells (CDJ, CC) 631 
and by (B) qRT-PCR on colonic L- and control cells. qRT-PCR data are presented as the 632 
geometric mean + upper SEM of the 2ΔCt data (n ≥ 3 each). (C) GLP-1 secretion was 633 
measured from mouse colon cultures in the presence of two concentrations of Ang (1-7). 634 
GLP-1 secretion is expressed as a percentage of total content. Results are shown as the mean 635 
+ SEM; n = 9–12 wells with 3 or 4 wells originating from a single mouse. Statistics were 636 
performed using one-way ANOVA followed by post hoc Dunnett's on log10 transformed 637 
data. 638 
Figure 6: Ang II induced effect on short circuit current in mouse distal colon. (A) Example 639 
traces showing changes in short circuit current recordings (Isc) from mouse distal colon 640 
mounted in Ussing chambers after basolateral application of Ang II (1 µmol/L). (B) Isc 641 
changes from colon tissue as in (A), but in the additional presence of basolateral NPY1R 642 
antagonist BIBP3226 (1 µmol/L) (C) Isc changes from colon tissue as in (A), but in the 643 
additional presence of bilateral AT1R antagonist candesartan (1 µmol/L). (D) Mean changes 644 
in Isc, recorded as in A-C, after application of Ang II alone or in the presence of Amiloride 645 
(Amil. 5 µmol/L), BIBP3226 (BIBP) or Candesartan (Can). ΔIsc was calculated as the 646 
difference between the means of short circuit currents from the 2-5 min period before and 30 647 
min period after the application of Ang II. Data are the mean + SEM from 4-5 tissue 648 
preparations for each condition, normalised for a surface area of 1 cm2. *p < 0.05, **p < 0.01 649 
compared with Ang II application alone using one-way ANOVA followed by post hoc 650 





  656 
Figure 2657 
 658 
  659 
Figure 3660 
 661 





Figure 5  667 
  668 
Figure 6 669 
 670 
  671 





Antigen sequence (if 
known)
Name of Antibody
Manufacturer, catalog #, 
and/or name of individual 
providing the antibody
Species raised in; 
monoclonal or polyclonal
Dilution used
GLP-1 Not available GLP-1 Antibody (C-17)
Santa Cruz Biotrechnology,
sc-7782
Goat, polyclonal  1:100
Angiotenin II type 1
receptor
Not available AT1 Antibody (306)
Santa Cruz Biotrechnology,
sc-579
Rabbit, polyclonal  1:100
